Despite stronger headwinds from slowing elective procedures, supply chain challenges and unfavorable foreign exchange rates, most total joint companies saw positive growth in Q222.
The WW Total Joints Market grew in Q222 despite slowing sequential growth compared to Q122’s growth. A slowdown in elective procedures late in the quarter along with continued supply chain challenges and the effect of foreign exchange rates resulted in stronger headwinds. SmartTRAK notes that several companies reported the carryover of these headwinds into Q3 that could dampen market recovery through year-end.
Among the many topics covered in detail in our comprehensive Q222 Total Joints Market Recap* are:
- Complete Q222 Total Joints Market Overview and Highlights
- SmartTRAK's Expert Analysis and Insights
- All Company News, Revenues, Data, Charts and Shares
- Top Players’ Results
- Q222 Regulatory Highlights and Approvals
For Q222, Zimmer Biomet* experienced positive WW growth in both Hips and Knees. Zimmer Biomet saw positive momentum of procedure volume recovery from the end of Q1 continuing through May with a bit of a slowdown in June. Stryker* also reported procedural volume recovery but noted that ...
*The entire unedited article and these links can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below. 
SmartTRAK is a comprehensive, easy-to-use, business intelligence solution for the Life Sciences Industry that provides breaking updates on pertinent company news, potential treatments and guidance, international survey results, statistical analysis by country, studies, trial results, financial impact and more. All subscribers receive a Daily Updates email containing the latest need-to-know news curated by our expert analysts. It's the perfect way to start your day! If you would like to learn more about SmartTRAK, just click here.
